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Disruption of Diacylglycerol Kinase Delta (DGKD) Associated
with Seizures in Humans and Mice
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We report a female patient with a de novo balanced translocation, 46,X,t(X;2)(p11.2;q37)dn, who exhibits seizures,
capillary abnormality, developmental delay, infantile hypotonia, and obesity. The 2q37 breakpoint observed in association
with the seizure phenotype is of particular interest, because it lies near loci implicated in epilepsy in humans and mice.
Fluorescence in situ hybridization mapping of the translocation breakpoints showed that no known genes are disrupted
at Xp11.2, whereas diacylglycerol kinase delta (DGKD) is disrupted at 2q37. Expression studies in Drosophila and mouse
suggest that DGKD is involved in central nervous system development and function. Electroencephalographic assessment
of Dgkd mutant mice revealed abnormal epileptic discharges and electrographic seizures in three of six homozygotes.
These findings implicate DGKD disruption by the t(X;2)(p11.2;q37)dn in the observed phenotype and support a more
general role for DGKD in the etiology of seizures.
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Epilepsy is a relatively common multifactorial neurolog-
ical disorder characterized by recurrent unprovoked sei-
zures, affecting ∼3% of the population during their life
span.1 Despite the evidence of a genetic component, es-
pecially in idiopathic epilepsy,2,3 and the frequency of sei-
zure disorders in humans, the genetic basis is difficult to
determine because of trait heterogeneity and complexity.
Not surprisingly, most genes identified as causative for
epilepsy syndromes encode ion channels, including sub-
units of sodium channels in generalized epilepsy with feb-
rile seizures (GEFS [MIM 604233]),4,5 potassium channels
in neonatal human epilepsy (EBN1 [MIM 121200], EBN2
[MIM 121201]),6 ligand gated ion channels (e.g., GABAA
receptor subunits) in childhood absence epilepsy (ECA2
[MIM 607681]),7 and neuronal nicotinic acetylcholine re-
ceptors in autosomal dominant nocturnal frontal lobe ep-
ilepsy (ENFL1 [MIM 600513] and ENFL3 [MIM 605375]).8
However, there are several examples of epilepsy genes that
do not fall into the channelopathy category, including
the Aristaless-related homeobox gene (ARX) in human
X-linked epilepsy (ISSX [MIM 308350]),9 the ethanola-
mine kinase gene (eas) in the Drosophila “easily shocked”
seizure mutant,10 the leucine-rich glioma inactivated 1
gene (LGI1) in a temporal lobe epilepsy (ADLTE [MIM
600512]),11 the very large G-protein coupled receptor 1
(VLGR1/MASS1) in febrile seizures (FEB4 [MIM 604352]),12
and the EF-hand domain–containing protein 1 (EFHC1)
in juvenile myoclonic epilepsy (EJM1 [MIM 254770].13
Such functional diversity makes gene discovery in epilepsy
especially challenging.
A successful gene-discovery approach in the setting of
functional diversity is analysis of balanced chromosomal
rearrangements in humans with developmental disorders.
Phenotypic abnormalities observed in association with
balanced chromosomal rearrangements can be explained
by alteration of expression of a gene(s) residing at or near
the chromosomal breakpoint(s). This principle serves as
the rationale for the Developmental Genome Anatomy
Project (DGAP), a study from which this case originated.
DGAP is an ongoing research endeavor approved by the
Partners HealthCare System Human Research Commit-
tee. In this study, the finding of an apparently balanced
t(X;2)(p11.2;q37)dn in an individual with epilepsy (des-
ignated “DGAP095”) provided an opportunity to identify
a gene liable for the phenotype. We found that the 2q37
breakpoint disrupts diacylglycerol kinase delta (DGKD),
and our expression studies support a role for DGKD in
CNS development and function. Electroencephalographic
(EEG) assessment of Dgkd knockdown mice revealed ab-
normal epileptic discharges in half of the mutant mice
evaluated, indicating DGKD involvement in the seizure
phenotype observed in DGAP095.
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Figure 1. A, DGAP095 capillary abnormalities on face and limbs. B, Ideogram of t(X;2)(p11.2;q37)dn present in DGAP095. C, Metaphase
spread following staining with DAPI and fluorescein-conjugated BrdU antibodies. Note that the normal chromosome X is BrdU-stained,
indicating its late-replication status.
At the time of assessment, DGAP095 was a mildly
obese 12-year-old female with epilepsy, congenital capil-
lary abnormalities, mild hypotonia, and a history of
developmental delay (fig. 1A). Her weight was at the
95th percentile, her height at the 10th percentile, and her
head circumference at the 90th percentile. She was the
first child of healthy, nonconsanguineous parents who
also have a healthy younger son. She was delivered vag-
inally after a normal pregnancy (birth weight 8 pounds
10 ounces; Apgar scores 8 and 9). She crawled and walked
at ages 2 and 3.5 years, respectively. At 3.5 years of age,
she received the diagnosis of generalized tonic clonic sei-
zures, which evolved into drop attacks at age 5 years that
eventually subsided; at 11 years of age, she developed star-
ing events with an occasional myoclonic component, and
currently she has 1–2 generalized tonic clonic seizures per
week. DGAP095 first exhibited cognitive delay at the age
of 18 mo and verbal/auditory processing difficulties char-
acterized by delayed responses and perseveration. She
also experienced self-stimulatory behavior, including hair
pulling, leg slapping, hand flapping, and echolalia. Sei-
zures in conjunction with behavioral findings are consis-
tent with the Lennox-Gastaut syndrome form of epi-
lepsy.14 Brain magnetic resonance imaging did not show
any abnormalities, and comprehensive metabolic testing
showed results within normal limits. A skin biopsy did
not reveal any pathological changes. Chromosomal anal-
ysis revealed an apparently balanced de novo trans-
location between chromosomes X and 2, designated
46,X,t(X;2)(p11.2;q37)dn (fig. 1B). To exclude the possi-
bility that her clinical phenotype reflected some form of
genomic imbalance, nonrandom inactivation of the nor-
mal X chromosome was confirmed by BrdU-based repli-
cation studies (fig. 1C), and no copy number alterations
were detected by whole-genome array comparative ge-
nome hybridization (CGH) at a resolution of ∼1 Mb
(GenomeChip V1.2 Human BAC Arrays [Spectral Gen-
omics]). The potential etiology of the phenotype due to
the t(X;2) was supported by phenotypic overlap between
DGAP095 and patients with del(2)(q37),15–19 genetic link-
age studies implicating 2q36 as a seizure-susceptibility
locus,20,21 and the fact that the mouse chromosomal region
with homologous synteny to human 2q37 is reported to
contain a seizure susceptibility locus.22 Thus, the cytoge-
netic anomaly in DGAP095, in conjunction with the pub-
lished linkage data, provided a clue to the location of a
potential epilepsy gene at 2q37.
Consecutive FISH experiments with BACs, either di-
rectly labeled with SpectrumOrange and SpectrumGreen
(Abbott Molecular/Vysis) or indirectly labeled with biotin,
were employed for initial narrowing of the breakpoint
regions. On chromosome 2, BAC clone RP11-400N9
showed hybridization signals localized to both the der(2)
and der(X) chromosomes, demonstrating that it spanned
the breakpoint (fig. 2A). FISH with another BAC clone,
RP11-79G2, which overlaps clone RP11-400N9, revealed
that it also hybridized to both derivative chromosomes,
thus placing the breakpoint within a 64-kb region of
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Figure 2. Mapping of the breakpoint on chromosome 2. A, Representative metaphase spread following FISH with clone RP11-400N9
(left) and RP11-79G2 (right); both probes are biotin labeled and detected by FITC-conjugated avidin. FISH signals are detected on the
normal chromosome 2, der(X), and der(2), indicating that the breakpoint is contained within the same genomic sequence on RP11-
400N9 and RP11-79G2. B, Refinement of the breakpoint region, performed using Southern blot hybridization with a 1,363-bp radioactive
PCR probe from the chromosome 2 breakpoint region. Red arrows indicate novel aberrant restriction fragments in DGAP095 DNA caused
by chromosomal rearrangement. C, Orientation of the RP11-400N9 and RP11-79G2 clones relative to each other (and reflective of uneven
split signals on the derivative chromosomes). The defined breakpoint region falls within the first intron of DAG kinase delta (DGKD),
as shown on the DGKD structural diagram, where numbered boxes represent exons. Restriction sites of the enzymes used for the Southern
blot are indicated by arrows, and the location of the PCR probe is represented by a red rectangle. D, Representative metaphase
chromosomes X, 2, der(2), and der(X) after hybridization with DGKD cDNA labeled with FITC. Note the absence of DGKD hybridization
signal on the der(2). (Chromosome X subtelomeric probe labeled with SpectrumOrange was used to facilitate identification of the
der(X).)
overlap (fig. 2A and 2C). Analyses of National Center for
Biotechnology Information and University of California
Santa Cruz gene maps indicated that the breakpoint on
chromosome 2 disrupted DGKD. For further breakpoint
refinement, Southern blot analyses hybridized with radio-
active PCR probes from the overlapping area were em-
ployed and narrowed the breakpoint region to 581 bp
within intron 1 (fig. 2B and 2C). Indirect labeling with
biotin and subsequent amplification of the signal by use
of avidin and anti-avidin conjugated with FITC (Roche)
were used for FISH, with a cDNA for DGKD (KIAA0145,
clone ha00914 [Kazusa DNA Research Institute]). The
DGKD cDNA showed expected hybridization signals on
both the normal chromosome 2 and der(X) (fig. 2D). No
DGKD hybridization was observed on the der(2), because
of a very small target sequence (a single exon), confirming
translocation of the majority of DGKD to the der(X). The
breakpoint on the X chromosome was found to reside
within BAC clone RP11-8A2 (data not shown). At the time
of mapping, this BAC represented a draft clone; however,
it overlapped several fully sequenced clones. On the basis
of the sequence of these overlapping clones, PCR probes
were designed and used for FISH to narrow the breakpoint
region to 4.1 kb (fig. 3A and 3B). Southern blot analyses
further localized the X chromosome breakpoint to a 1,393-
bp region (figs. 3A and 3C). This chromosomal break did
not occur within any known or putative genes, with the
closest gene residing at a distance of 5.1 kb. Expression of
this gene, WDR13, appeared to be unaffected by the trans-
location by RT-PCR analysis (data not shown). Interest-
ingly, both breakpoint regions contained Alu-Sx repetitive
elements, which could provide a molecular mechanism
for the formation of the translocation by illegitimate re-
combination between chromosomes X and 2.
3′-RACE analysis (Qiagen) performed on RNA isolated
from DGAP095 lymphoblastoid cells showed the presence
of two alternatively spliced DGKD transcripts but no evi-
dence of chimeric transcripts. This result is expected, be-
cause of the absence of an ORF close to the reciprocal
breakpoint on the X chromosome. Also, to exclude hidden
heterozygosity in DGAP095, the coding region of DGKD
was analyzed, with the exception of a highly CG-rich re-
petitive region encompassing exon 1 that was refractory
to sequence analysis, and no mutations were found in the
regions assessed. The absence of novel transcripts and of
any sequence mutations in the second DGKD allele im-
plies that DGAP095’s abnormal phenotype is due to DGKD
haploinsufficiency.
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Figure 3. Mapping of the breakpoint on chromosome X. A, Graphic representation of orientation of PCR probes used for FISH and
map of restriction sites of the enzymes used for the Southern blot, with the probe location represented by a red rectangle. B, Metaphase
chromosomes following FISH with PCR probe 1 (left) and PCR probe 2 (right); both probes are labeled by biotin and detected by FITC-
conjugated avidin. Probe 1 hybridizes to the normal chromosome X and to the der(2), whereas probe 2 hybridizes to the normal X and
der(X), indicating that the breakpoint is located within the sequence flanked by the probes. C, Southern blot hybridized to the 371-
bp radioactive PCR probe from the chromosome X breakpoint region (originally defined by FISH). (No aberrant fragment is present in
the XbaI digest because the breakpoint occurs outside of the area flanked by XbaI sites.)
Whole-mount in situ hybridization experiments were
performed to investigate Dgkd developmental expression
in both mouse and fly. Embryos were fixed in 4% para-
formaldehyde/PBS, permeabilized with proteinase K, and
then hybridized to a digoxigenin-labeled probe antisense
to a unique sequence within the respective Dgkd ortho-
logs. Probes were prepared by RT-PCR followed by sub-
cloning into the pDrive cloning vector (Qiagen) and la-
beled using a digoxigenin RNA labeling kit (Boehringer
Mannheim). Expression of the presumptive Dgkd fly or-
tholog (CG31187), identified by two-directional BLAST
analysis, was confined to the developing brain and ventral
nerve cord of late-stage (stage 16) fly embryos (fig. 4A).
Murine Dgkd, identified by homologous synteny, dis-
played prominent expression in the developing midbrain
and forebrain of E12.5 embryos (fig. 4B). Radioactive in
situ hybridization was used to determine Dgkd expression
patterns in adult mouse brain. A [35S]-labeled Dgkd ribo-
probe specific to the unique 3′ UTR region of Dgkd was
generated by PCR followed by subcloning into the pCR
2.1-TOPO vector (Invitrogen) and was synthesized and la-
beled using an in vitro transcription kit (Roche). Sagittal
sections of mouse brain were hybridized to 106 counts/
min of riboprobe and were exposed at 4C for 2 wk in
Kodak NTB emulsion. After exposure, slides were devel-
oped and counterstained with hematoxylin. The study re-
vealed a broad neuronal expression pattern with particular
prominence in pyramidal neurons of the neocortex and
hippocampus, and also within internal granule cell neu-
rons of the cerebellum (fig. 4C). The observed Dgkd ex-
pression patterns suggest the relevance of Dgkd to neural
development and brain pathophysiology.
To evaluate further the role of DGKD disruption in the
DGAP095 phenotype, a Dgkd mutant mouse was gener-
ated. Mouse protocols were approved by the Institutional
Animal Care and Use Committee at Harvard Medical
School. A mouse embryonic stem cell line (RRT600, strain
Ola/129) developed using gene-trap methodology was
identified in the BayGenomics database by use of BLAST
with human DGKD cDNA sequence. RT-PCR of the RNA
pool isolated from the mouse embryos and the brain of
adult mice showed that the RRT600 sequence tag belonged
to the first exon of murine Dgkd; thus, the ES cell line was
designated as DgkdGt(pGTlxf)Byg. The precise location of the
gene-trap vector pGTlxf insertion site was determined to
be within the first intron of Dgkd (fig. 5A and 5B). The
gene-trap vector possesses a strong splice-site–acceptor se-
quence (i.e., Engrailed-2 [En2] exon), and, as a result of
its integration, the first exon splices to the vector se-
quences resulting in generation of a fusion transcript be-
tween Dgkd exon 1 and the gene-trap vector. Because Dgkd
is expressed in adult wild-type mouse brain, RT-PCR stud-
ies were performed on total RNA isolated from mutant
mouse brain (RNeasy kit [Qiagen]) to validate that the
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Figure 4. Whole-mount in situ hybridization showing expression
of Dgkd orthologs. A, Stage 16 fly embryo hybridized to the Dro-
sophila Dgkd antisense probe. Note expression in brain and ventral
nerve cord. B, E12.5 mouse embryo hybridized to the mouse Dgkd
antisense probe. Note prominent expression in forebrain and mid-
brain. C, In situ hybridization performed using a 3′ UTR probe to
the Dgkd transcript on adult wild-type mouse neocortex and cer-
ebellum. Dark granules represent Dgkd transcripts. Neocortex: mod-
erate to high Dgkd expression in large pyramidal neurons (pn and
arrows) and relatively absent to low in small cells with the mor-
phology of glia (arrowheads). In the cerebellum, expression is
relatively low in glia and neurons of the molecular layer (ml),
intermediate within the Purkinje cell and Bergmann glial cell layer
(pc and arrows point to Purkinje cells), and highest in granule
neurons within the internal granule cell layer (igl).
gene-trap insertion affected Dgkd expression. Homozy-
gous mutant mice showed absent Dgkd expression in
forebrain and midbrain tissues; however, faint expres-
sion was detected in cerebellum (fig. 5C). Therefore, the
DgkdGt(pGTlxf)Byg allele appears to represent a knockdown or
hypomorphic allele rather than a categoric null. In ad-
dition, Dgkd encodes two alternative transcripts. Insertion
of the gene-trap vector affected expression of the most
abundant transcript, but expression of a second, low-
abundance transcript that initiates in exon 2 was com-
paratively unaffected (data not shown). Of note, the site
of the gene-trap insertion is analogous to the DGKD dis-
ruption in DGAP095, in which the translocation break-
point falls within the first intron. Also, the knockdown
nature of the introduced mutation approximates the hap-
loinsufficient state for DGKD in DGAP095. Thus, the
knockdown mutant represents a directly relevant model
for assessing DGAP095’s genetic defect.
Dgkd homozygous mutant mice were viable and fertile.
Twenty-four mutant mice of different ages (14 homozy-
gotes and 10 heterozygotes) were assessed for gross ana-
tomical and histopathological abnormalities by complete
necropsy, and no consistent morphological abnormali-
ties were noted. Nevertheless, these analyses do not ex-
clude more-subtle physical abnormalities or those requir-
ing additional physiological studies. A potential seizure
phenotype in mutant mice was initially investigated by a
seizure-susceptibility study using a subthreshold dose of
pentylenetetrazol (PTZ) (40 mg/kg) in 10 homozygous
mutants at the age of 2 mo (5 females and 5 males) and
in 10 wild-type littermate controls (5 females and 5 males).
The latency and severity of seizures were evaluated
as described elsewhere,22 and scores were compared be-
tween wild-type and knockdown littermates. No signif-
icant difference in susceptibility to PTZ-induced seizures
was noted.
To examine potential electroencephalic abnormalities,
EEG/electromyography (EMG) assessments were per-
formed on six homozygotes (three females and three
males) and two wild-type male littermate controls at 12
wk of age. Animals were implanted with two EMG elec-
trodes inserted into neck muscles and four EEG electrodes
on the skull at the following coordinates: 2 mm lateral to
and 1 mm anterior to the Bregma for the two front elec-
trodes, and 2 mm lateral to and 3 mm posterior to the
Bregma for the two rear electrodes. On the 4th d after
surgery, animals were wired to an MP150 physiological
signal recording device (Biopac Systems). Two channels of
EEG, one from each side of the brain, and one channel
of EMG data were recorded simultaneously from each an-
imal. High- and low-pass filters were 0.1 Hz and 100 Hz
for EEG and 1.0 Hz and 500 Hz for EMG, respectively.
Continuous EEG/EMG recording was allowed for all mice,
provided they had good signals, until the experiment was
discontinued on the 24th d after surgery. For each animal,
the continuous EEG was visually inspected to identify
electrographic seizure activity. Epileptiform activity was
recognized on the basis of commonly used principles of
EEG analysis, including the occurrence of epileptiform
spikes distinguished on the basis of morphology, electrical
field and amplitude, and changes in baseline activity with
an evolving pattern of rhythmic activity of higher am-
plitude than the baseline. The pattern of activity and the
specific morphology of the EEG activity were assessed by
an experienced electroencepalographer (A.J.C.). For each
animal, two channels of EEG recording were available
along with a single channel of EMG recording to allow
the assessment of associated muscle activity. In three mu-
tant mice (two males and one female), discrete seizures
were identified in association with rhythmic EMG activ-
ities, whereas no seizures were noted in the wild-type
mice. One mutant mouse had a bilateral ictal discharge
(fig. 5D), whereas, in the other two mutants, the ictal EEG
activity was confined to a single hemisphere, suggesting
a focal origin. Analysis of contemporaneous EMG activity
excluded the possibility that the abnormal EEG activity
represented movement artifact. Interestingly, one of the
mutant animals had frequent, high-amplitude (800–1000
microvolts), interictal epileptiform spikes occurring once
every 10–120 s. In that animal, direct observation was
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Figure 5. A, Graphic representation of the gene-trap vector insertion within Dgkd intron 1. Numbered boxes represent exons, arrows
represent primers used for genotyping and expression assays, and double-sided arrows represent expected amplicons. B, Representative
genotyping assay performed on wild-type, heterozygous (het), and homozygous (homo) mice. C, Dgkd expression analysis in brain
tissues from homozygous and wild-type mice. D, EEG recording showing epileptiform activity in a Dgkd knockdown mutant mouse. A
sudden onset of ictal electrographic discharge is recorded from both hemispheres (upper channel [red] and middle channels [blue]
represent left and right hemispheres, respectively), with higher amplitude on the left. The frequency and amplitude of the discharge
evolves in a manner typical of seizure activity. Simultaneous EMG recording (lower channel [green]) demonstrates fast, low-voltage
frequencies that might reflect fine-motor activity associated with electrographic seizure discharge. (It is possible that the EMG channel
is contaminated with EEG activity, as the recording electrode is placed close to the head.) No gross movements are observed, excluding
the artifact as a cause of the EEG changes. Time scale is 5 s per major division. Amplitude scale is 800 microvolts per major division.
made during the occurrence of an electrographic seizure;
a long spike train was observed when the mouse was mo-
tionless in a normal sleeping posture, and only a fine jit-
tering motion of the head was noted. Postmortem anal-
yses excluded the possibility of artifacts introduced by
improper electrode implantation. The fact that only half
of the mutant mice exhibited seizures could be due to the
mixed C57BL/6 X Ola/129 genetic background in which
the stock was maintained; the nature of the hypomorphic
mutation, which could attenuate robust expression of the
phenotype; or the limited observation period.
In respect to the other DGAP095 clinical features, the
potential vascular and obesity phenotypes were not ex-
haustively investigated in mutant mice. The absence of
apparent capillary abnormalities in mutant mice does not
exclude the potential presence of a physiological abnor-
mality that has not been observed. Also, the mutant mice
tended to be overweight, but the comprehensive analysis
of the obesity trait was hindered by the propensity of
C57BL/6 mice to become obese. It must also be noted that
mouse models do not always fully recapitulate human
phenotypes.
Interestingly, 2 (9%) of 21 homozygous mutants and 2
(7%) of 28 heterozygotes (monitored for at least 5 mo)
developed tumors. One homozygous 11-mo-old male
mouse received a diagnosis of squamous cell carcinoma
of the tongue (a rare murine cancer), one 15-mo-old ho-
mozygous male mouse developed hepatoma, and two het-
erozygous mice 5.5 mo and 16 mo of age had histiocytic
sarcoma. In contrast, 0 of 7 wild-type littermates, moni-
tored until 18 mo of age, succumbed to cancer. The finding
of tumors in 4 (8%) of 49 of mutant mice could be related
potentially to altered DAG signaling.
Recently, a Dgkd null knockout mouse model has been
described.23 These mice developed respiratory difficulties
and were invariably dead within the first 24 h after birth.
Besides small size, the newborn pups were also noted to
have open eyelids. A dramatically reduced viability of the
Dgkd homozygous null mice demonstrates the critical
function of Dgkd expression. The drastic difference in the
phenotype of our knockdown mutants in comparison
with the knockout null mutants is interpreted to be due
to their hypomorphic nature and potentially to the fact
that expression of only one isoform is affected.
As in mice, DGKD in humans has two alternatively
spliced isoforms with the low-abundance transcript ini-
tiating in exon 2 and being present in spleen, ovary, and
some tumor-derived cells.24 Both isoforms possess kinase
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activity and can form homo- and hetero-oligomers but are
expressed under different regulatory mechanisms and
have different intracellular localization in response to
phorbol ester stimulation.24 The t(X;2) in DGAP095 causes
abolishment of expression of the abundant DGKD isoform
as it separates exon 1 from the rest of the gene. It is pos-
sible that expression of the other isoform also could be
affected if its transcription requires an upstream regulatory
element. The function of the DGKD gene product supports
its involvement in the seizure phenotype. It belongs to a
family of diacylglycerol (DAG) kinases that phosphorylate
DAG and convert it to phosphatidic acid (PA). Both DAG
and PA are important second messengers in a pathway of
lipid signaling that has been implicated in epilepsy and
other neurological diseases, such as depression and Alz-
heimer disease.25–27 Moreover, mice deficient in the gene
encoding DAG kinase epsilon, Dgke, display an altered
susceptibility to seizures.28 Therefore, the patient’s phe-
notype could be explained by an altered balance between
DAG and PA caused by DGKD haploinsufficiency. Of spe-
cial interest, in this respect, are DAG-gated transient re-
ceptor potential cation channels (e.g., TRPC3, -6, and -7),
in which DAG binding directly opens the channel.29,30 Ex-
istence of these channels in the brain places DAG kinases
in proximity to the category of neuronal channelopathies.
It is of note that the neurological and capillary abnor-
malities in DGAP095 could potentially have a common
etiology, because vascular and neural development share
many common genetic pathways and signaling mecha-
nisms.31 For example, the angiogenic factor VEGF is also
involved in the stimulation of neurogenesis.32 Intrigu-
ingly, the downstream targets of DAG kinases are impli-
cated in the regulation of angiogenesis and VEGF-induced
signaling,33–35 and DAG-gated channels are believed to
play a critical role in vasoconstrictor-activated cation in-
flux and regulation of arterial myogenic tone.36
In summary, the collective evidence, including direct
disruption of DGKD by the t(X;2) in an individual with
epilepsy, expression of DGKD orthologs in the developing
nervous system in Drosophila and mouse embryos, broad
expression in regions of the mouse brain known to pro-
duce seizures, and the occurrence of seizures in Dgkd mu-
tant mice provide strong support for DGKD’s involvement
in epilepsy disorders in humans and mice.
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